Brokerages expect that LivaNova PLC (NASDAQ:LIVN) will announce earnings per share (EPS) of $0.91 for the current quarter, according to Zacks. Three analysts have made estimates for LivaNova’s earnings, with estimates ranging from $0.88 to $0.93. LivaNova reported earnings of $1.01 per share in the same quarter last year, which indicates a negative year over year growth rate of 9.9%. The firm is scheduled to report its next quarterly earnings report on Wednesday, August 8th.
According to Zacks, analysts expect that LivaNova will report full year earnings of $3.58 per share for the current year, with EPS estimates ranging from $3.57 to $3.60. For the next fiscal year, analysts expect that the company will post earnings of $3.94 per share, with EPS estimates ranging from $3.89 to $4.00. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for LivaNova.
LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, May 2nd. The company reported $0.68 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.03. LivaNova had a positive return on equity of 9.23% and a negative net margin of 1.99%. The business had revenue of $250.40 million during the quarter, compared to analysts’ expectations of $245.18 million. During the same quarter in the previous year, the business earned $0.67 EPS. The company’s revenue for the quarter was up 10.4% on a year-over-year basis.
LIVN has been the subject of a number of research reports. BidaskClub upgraded LivaNova from a “hold” rating to a “buy” rating in a report on Saturday, March 24th. Zacks Investment Research cut LivaNova from a “hold” rating to a “sell” rating in a report on Tuesday, May 1st. BTIG Research reiterated a “hold” rating on shares of LivaNova in a report on Thursday, May 3rd. ValuEngine cut LivaNova from a “strong-buy” rating to a “buy” rating in a report on Thursday, May 17th. Finally, Stifel Nicolaus started coverage on LivaNova in a research report on Friday, June 8th. They set a “buy” rating and a $115.00 price target on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $85.88.
In related news, insider David S. Wise sold 1,500 shares of the business’s stock in a transaction that occurred on Friday, June 15th. The stock was sold at an average price of $104.46, for a total transaction of $156,690.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Francesco Bianchi sold 1,830 shares of the business’s stock in a transaction that occurred on Wednesday, May 23rd. The stock was sold at an average price of $83.81, for a total value of $153,372.30. The disclosure for this sale can be found here. Insiders have sold a total of 27,072 shares of company stock worth $2,542,618 over the last three months. 0.41% of the stock is currently owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Advisors Preferred LLC acquired a new position in LivaNova during the 1st quarter worth approximately $113,000. Cubist Systematic Strategies LLC acquired a new position in LivaNova during the 1st quarter worth approximately $174,000. QS Investors LLC raised its position in shares of LivaNova by 27,255.6% in the 4th quarter. QS Investors LLC now owns 2,462 shares of the company’s stock valued at $197,000 after purchasing an additional 2,453 shares in the last quarter. Rehmann Capital Advisory Group acquired a new position in shares of LivaNova in the 4th quarter valued at approximately $216,000. Finally, Macquarie Group Ltd. raised its position in shares of LivaNova by 100.0% in the 4th quarter. Macquarie Group Ltd. now owns 2,800 shares of the company’s stock valued at $224,000 after purchasing an additional 1,400 shares in the last quarter. 84.62% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NASDAQ:LIVN traded down $1.36 during trading on Friday, reaching $99.82. 278,701 shares of the stock were exchanged, compared to its average volume of 546,291. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.51 and a current ratio of 1.85. LivaNova has a 12-month low of $59.12 and a 12-month high of $105.90. The stock has a market capitalization of $4.90 billion, a P/E ratio of 30.16, a PEG ratio of 2.98 and a beta of 0.76.
LivaNova Company Profile
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.